2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-122178
    5-trans U-44069 330796-57-1 98%
    5-trans U-44069 is the trans isomer of the thromboxane receptor agonist U-44069 (HY-121825). 5-trans U-44069 inhibits prostaglandin E2 synthase activity.
    5-trans U-44069
  • HY-122211
    MRS2802 1047980-53-9 98%
    MRS2802 is a P2Y14 receptor agonist with an EC50 value of 63 nM. MRS2802 can effectively activate the P2Y14 receptor and may play a role in regulating platelet function. The selectivity and activity of MRS2802 are conducive to in-depth research on the biological functions and pharmacological properties of P2Y receptors. The development of MRS2802 provides a potential inhibitory strategy for the search for new antiplatelet compounds.
    MRS2802
  • HY-122221
    KUM 32 28717-34-2 98%
    KUM 32 is a potent antagonist of epinephrine-induced platelet aggregation. KUM 32 is an adenylate cyclase activity inhibitor. KUM 32 binds to the alpha 2 adrenergic receptor of human platelets.
    KUM 32
  • HY-122230
    UR-3216 220386-65-2 98%
    UR-3216 is a selective, and orally active platelet surface glycoprotein (GPIIb/IIIa) receptor antagonist. UR-3216 has the potential for cardiovascular diseases research.
    UR-3216
  • HY-122282
    AZ11657312 804561-22-6 98%
    AZ11657312 is a P2X7 receptor antagonist with activity to restore stress natriuresis. AZ11657312 significantly increased renal medullary perfusion, only in mice treated with angiotensin II. AZ11657312 improves tissue oxygenation by blocking P2X7R, especially in areas of the kidney that are underoxygenated. Administration of AZ11657312 increased sodium excretion up to sixfold while normalizing blood pressure.
    AZ11657312
  • HY-122320
    Phytosterols 949109-75-5 98%
    Phytosterols are anticancer agents. Phytosterols can be used in research related to cardiovascular disease and cancer.
    Phytosterols
  • HY-122331
    Norbormide 991-42-4 98.91%
    Norbormide shows vasoconstrictor activity by blocking calcium channel. The activity of Norbormide is species- and tissue-specific, endothelium independent, and is restricted to the peripheral arteries of rat. Norbormide is also a toxicant, and the oral LD50s in mouse, hamster, guinea pig and rabbit are 2250, 140, 620, and 1000 mg/kg.
    Norbormide
  • HY-122364
    Bucumolol hydrochloride 36556-75-9 98%
    Bucumolol hydrochloride is a β-adrenergic receptor antagonist that can slow heart rate (negative chronotropic effect) and reduce cardiac contractility (negative inotropic effect). Bucumolol hydrochloride has antiarrhythmic and local anesthetic activity and can be used in the study of cardiovascular diseases.
    Bucumolol hydrochloride
  • HY-122423
    Desethylamiodarone 83409-32-9 98%
    Desethylamiodarone (N-Deethylamiodarone) is the major metabolite of antiarrhythmic compound Amiodarone (HY-14187). Desethylamiodarone has antiarrhythmic activity. Desethylamiodaron also induces cancer cell apoptosis.
    Desethylamiodarone
  • HY-122499
    Ciprostene calcium 81703-55-1 98%
    Ciprostene calcium is a prostacyclin analogue.Ciprostene calcium inhibits adenosine diphosphate-induced platelet aggregation. Ciprostene calcium can be used for research of peripheral vascular disease.
    Ciprostene calcium
  • HY-122537
    Arotinolol hydrochloride 68377-91-3 98%
    Arotinolol hydrochloride is a nonselective α/β-adrenergic receptor blocker and a vasodilating β-blocker. Arotinolol hydrochloride also shows potency for inhibiting the binding of the radioligand 125I-ICYP to 5HT1B-serotonergic receptor sites. Arotinolol hydrochloride is an antihypertensive agent for the treatment of a variety of cardiovascular pathologies as well as non-cardiovascular diseases.
    Arotinolol hydrochloride
  • HY-122542
    PPACK 71142-71-7 98%
    PPACK is potent, selective and irreversible thrombin inhibitor. PPACK can be used an alternative anticoagulant to lithium heparin (LiHep) for blood gas and whole-blood electrolyte analyses. PPACK is also a plasminogen activator (rt-PA) inhibitor. PPACK can inhibit the binding of rt-PA to plasma protease inhibitors.
    PPACK
  • HY-122560
    VU0134992 755002-90-5 98%
    VU0134992 is the first subtype-preferring, orally active and selective Kir4.1 potassium channel pore blocker, with an IC50 of 0.97 µM. VU0134992 is 9-fold selective for homomeric Kir4.1 over Kir4.1/5.1 concatemeric channels (IC50=9 µM) at -120 mV.
    VU0134992
  • HY-122592
    Zifaxaban 1378266-98-8 98%
    Zifaxaban is an orally active, competitively and selective Factor Xa (FXa) inhibitor with an IC50 of 11.1 nM for human FXa. Zifaxaban shows >10000-fold greater selectivity than other serine proteases. Zifaxaban can be used for the arterial and venous thrombosis research.
    Zifaxaban
  • HY-122792
    Phenyramidol Hydrochloride 326-43-2 98%
    Phenyramidol hydrochloride is an anticoagulant and analgesic with activity that increases detection sensitivity in biological samples. Phenyramidol hydrochloride can be oxidized in aqueous media by electrochemical methods to achieve its quantitative analysis. The detection of Phenyramidol hydrochloride using an amino-functionalized multi-walled carbon nanotube-modified glassy carbon electrode showed significant enhancement of the current peak.
    Phenyramidol Hydrochloride
  • HY-122874
    DI-404 2187412-79-7 98%
    DI-404 is a potent inhibitor of DCN1 with a KKd value of 6.7 nM. DI-404 selectively inhibits neddylation of cullin 3 in a dose-dependent manner.
    DI-404
  • HY-122933
    Kurarinol 855746-98-4 98%
    Kurarinol is a flavanone found in the root of Sophora flavescens. Kurarinol is a competitive tyrosinase inhibitor, with IC50 of 0.1 μM for mushroom tyrosinase.
    Kurarinol
  • HY-122951
    Eburicoic acid 560-66-7 98.97%
    Eburicoic acid protects the liver from CCl4-induced hepatic damage via antioxidant and anti-inflammatory mechanisms. And Eburicoic acid has antidiabetic and antihyperlipidemic effects.
    Eburicoic acid
  • HY-123112
    Hoe 892 75111-35-2 98%
    Hoe 892 (S792892A) is an orally active prostacyclin derivative with antiplatelet aggregation and vasodilatory activity. Hoe 892 can be used in the study of cardiovascular diseases such as thrombosis.
    Hoe 892
  • HY-123123
    RS-61756-007 121571-14-0 98%
    RS-61756-007 is a selective thromboxane receptor (TP) agonist with high activity at the TP receptor. RS-61756-007 showed agonism at TP and FP receptors in in vitro studies but had no activity at other receptor subtypes. The effects of RS-61756-007 can be antagonized in a similar manner by the TP antagonist SQ 29,548.
    RS-61756-007
Cat. No. Product Name / Synonyms Application Reactivity